HEADER SIGNALING PROTEIN 07-JUN-18 6GQO TITLE CRYSTAL STRUCTURE OF HUMAN KDR (VEGFR2) KINASE DOMAIN IN COMPLEX WITH TITLE 2 AZD3229-ANALOGUE (COMPOUND 18) COMPND MOL_ID: 1; COMPND 2 MOLECULE: VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: VEGFR-2,FETAL LIVER KINASE 1,FLK-1,KINASE INSERT DOMAIN COMPND 5 RECEPTOR,KDR,PROTEIN-TYROSINE KINASE RECEPTOR FLK-1,VEGFR-2,FETAL COMPND 6 LIVER KINASE 1,FLK-1,KINASE INSERT DOMAIN RECEPTOR,KDR,PROTEIN- COMPND 7 TYROSINE KINASE RECEPTOR FLK-1; COMPND 8 EC: 2.7.10.1; COMPND 9 ENGINEERED: YES; COMPND 10 OTHER_DETAILS: HUMAN KDR KINASE DOMAIN D807-D1171 WITH AN INTERNAL COMPND 11 DELETION OF T940-E990, REPLACED BY A SINGLE VALINE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: KDR, FLK1, VEGFR2; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF21 KEYWDS RECEPTOR TYROSINE KINASE, INHIBITOR, ONCOLOGY, GASTROINTESTINAL KEYWDS 2 STROMAL TUMOUR, STRUCTURE-BASED DRUG DESIGN, SIGNALING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR D.J.OGG,M.SCHIMPL,C.J.HARDY,R.C.OVERMAN,M.J.PACKER,J.G.KETTLE, AUTHOR 2 R.ANJUM,E.BARRY,D.BHAVSAR,C.BROWN,A.CAMPBELL,K.GOLDBERG,M.GRONDINE, AUTHOR 3 S.GUICHARD,T.HUNT,O.JONES,X.LI,O.MOLEVA,S.PEARSON,W.SHAO,A.SMITH, AUTHOR 4 J.SMITH,D.STEAD,S.STOKES,M.TUCKER,Y.YE REVDAT 4 17-JAN-24 6GQO 1 REMARK REVDAT 3 31-OCT-18 6GQO 1 JRNL REVDAT 2 03-OCT-18 6GQO 1 JRNL REVDAT 1 19-SEP-18 6GQO 0 JRNL AUTH J.G.KETTLE,R.ANJUM,E.BARRY,D.BHAVSAR,C.BROWN,S.BOYD, JRNL AUTH 2 A.CAMPBELL,K.GOLDBERG,M.GRONDINE,S.GUICHARD,C.J.HARDY, JRNL AUTH 3 T.HUNT,R.D.O.JONES,X.LI,O.MOLEVA,D.OGG,R.C.OVERMAN, JRNL AUTH 4 M.J.PACKER,S.PEARSON,M.SCHIMPL,W.SHAO,A.SMITH,J.M.SMITH, JRNL AUTH 5 D.STEAD,S.STOKES,M.TUCKER,Y.YE JRNL TITL DISCOVERY OF JRNL TITL 2 N-(4-{[5-FLUORO-7-(2-METHOXYETHOXY) JRNL TITL 3 QUINAZOLIN-4-YL]AMINO}PHENYL)-2-[4-(PROPAN-2-YL)-1 JRNL TITL 4 H-1,2,3-TRIAZOL-1-YL]ACETAMIDE (AZD3229), A POTENT PAN-KIT JRNL TITL 5 MUTANT INHIBITOR FOR THE TREATMENT OF GASTROINTESTINAL JRNL TITL 6 STROMAL TUMORS. JRNL REF J. MED. CHEM. V. 61 8797 2018 JRNL REFN ISSN 1520-4804 JRNL PMID 30204441 JRNL DOI 10.1021/ACS.JMEDCHEM.8B00938 REMARK 2 REMARK 2 RESOLUTION. 1.87 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.87 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 48.82 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 3 NUMBER OF REFLECTIONS : 27268 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.174 REMARK 3 R VALUE (WORKING SET) : 0.172 REMARK 3 FREE R VALUE : 0.207 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.150 REMARK 3 FREE R VALUE TEST SET COUNT : 1403 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.000 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 14 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.87 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.94 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 95.01 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2726 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2160 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2602 REMARK 3 BIN R VALUE (WORKING SET) : 0.2150 REMARK 3 BIN FREE R VALUE : 0.2290 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.55 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 124 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2460 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 128 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 36.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 47.98 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 5.08210 REMARK 3 B22 (A**2) : 0.09480 REMARK 3 B33 (A**2) : -5.17690 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 4.00830 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.210 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.127 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.119 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.128 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.120 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.958 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.946 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2586 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 3504 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 906 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 54 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 377 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2586 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 321 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 3026 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 0.97 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.21 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 17.52 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: { A|* } REMARK 3 ORIGIN FOR THE GROUP (A): 21.5136 -0.5025 12.2711 REMARK 3 T TENSOR REMARK 3 T11: -0.0899 T22: -0.0798 REMARK 3 T33: -0.0727 T12: -0.0023 REMARK 3 T13: -0.0032 T23: -0.0005 REMARK 3 L TENSOR REMARK 3 L11: 2.2077 L22: 1.8678 REMARK 3 L33: 1.3769 L12: -0.1509 REMARK 3 L13: 0.3958 L23: -0.3842 REMARK 3 S TENSOR REMARK 3 S11: 0.0087 S12: -0.3103 S13: -0.0112 REMARK 3 S21: 0.1800 S22: -0.0425 S23: -0.0108 REMARK 3 S31: -0.0290 S32: 0.2133 S33: 0.0338 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6GQO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 07-JUN-18. REMARK 100 THE DEPOSITION ID IS D_1200010416. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-SEP-15 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I02 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97949 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M-F REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XIA2 REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 27358 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.870 REMARK 200 RESOLUTION RANGE LOW (A) : 56.460 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 200 DATA REDUNDANCY : 6.400 REMARK 200 R MERGE (I) : 0.04800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.87 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.97 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.4 REMARK 200 DATA REDUNDANCY IN SHELL : 5.00 REMARK 200 R MERGE FOR SHELL (I) : 0.54500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 3WZD REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.36 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.38 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 8 % PEG 8000, 0.1 M TRIS PH 8.5, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 28.22850 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 0 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15530 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 0.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 806 REMARK 465 ASP A 807 REMARK 465 PRO A 808 REMARK 465 ASP A 809 REMARK 465 GLU A 810 REMARK 465 GLN A 1169 REMARK 465 GLN A 1170 REMARK 465 ASP A 1171 REMARK 465 GLU A 1172 REMARK 465 ASN A 1173 REMARK 465 LEU A 1174 REMARK 465 TYR A 1175 REMARK 465 PHE A 1176 REMARK 465 GLN A 1177 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A 811 CG CD1 CD2 REMARK 470 PRO A 812 CG CD REMARK 470 LEU A 813 CG CD1 CD2 REMARK 470 ARG A 842 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 844 -69.21 -92.56 REMARK 500 ARG A1027 -6.46 81.09 REMARK 500 ASP A1028 45.86 -147.86 REMARK 500 SER A1037 -165.51 -108.04 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue F82 A 1201 DBREF 6GQO A 806 939 UNP P35968 VGFR2_HUMAN 806 939 DBREF 6GQO A 941 1171 UNP P35968 VGFR2_HUMAN 991 1171 SEQADV 6GQO VAL A 940 UNP P35968 LINKER SEQADV 6GQO GLU A 1172 UNP P35968 EXPRESSION TAG SEQADV 6GQO ASN A 1173 UNP P35968 EXPRESSION TAG SEQADV 6GQO LEU A 1174 UNP P35968 EXPRESSION TAG SEQADV 6GQO TYR A 1175 UNP P35968 EXPRESSION TAG SEQADV 6GQO PHE A 1176 UNP P35968 EXPRESSION TAG SEQADV 6GQO GLN A 1177 UNP P35968 EXPRESSION TAG SEQRES 1 A 322 MET ASP PRO ASP GLU LEU PRO LEU ASP GLU HIS CYS GLU SEQRES 2 A 322 ARG LEU PRO TYR ASP ALA SER LYS TRP GLU PHE PRO ARG SEQRES 3 A 322 ASP ARG LEU LYS LEU GLY LYS PRO LEU GLY ARG GLY ALA SEQRES 4 A 322 PHE GLY GLN VAL ILE GLU ALA ASP ALA PHE GLY ILE ASP SEQRES 5 A 322 LYS THR ALA THR CYS ARG THR VAL ALA VAL LYS MET LEU SEQRES 6 A 322 LYS GLU GLY ALA THR HIS SER GLU HIS ARG ALA LEU MET SEQRES 7 A 322 SER GLU LEU LYS ILE LEU ILE HIS ILE GLY HIS HIS LEU SEQRES 8 A 322 ASN VAL VAL ASN LEU LEU GLY ALA CYS THR LYS PRO GLY SEQRES 9 A 322 GLY PRO LEU MET VAL ILE VAL GLU PHE CYS LYS PHE GLY SEQRES 10 A 322 ASN LEU SER THR TYR LEU ARG SER LYS ARG ASN GLU PHE SEQRES 11 A 322 VAL PRO TYR LYS VAL ALA PRO GLU ASP LEU TYR LYS ASP SEQRES 12 A 322 PHE LEU THR LEU GLU HIS LEU ILE CYS TYR SER PHE GLN SEQRES 13 A 322 VAL ALA LYS GLY MET GLU PHE LEU ALA SER ARG LYS CYS SEQRES 14 A 322 ILE HIS ARG ASP LEU ALA ALA ARG ASN ILE LEU LEU SER SEQRES 15 A 322 GLU LYS ASN VAL VAL LYS ILE CYS ASP PHE GLY LEU ALA SEQRES 16 A 322 ARG ASP ILE TYR LYS ASP PRO ASP TYR VAL ARG LYS GLY SEQRES 17 A 322 ASP ALA ARG LEU PRO LEU LYS TRP MET ALA PRO GLU THR SEQRES 18 A 322 ILE PHE ASP ARG VAL TYR THR ILE GLN SER ASP VAL TRP SEQRES 19 A 322 SER PHE GLY VAL LEU LEU TRP GLU ILE PHE SER LEU GLY SEQRES 20 A 322 ALA SER PRO TYR PRO GLY VAL LYS ILE ASP GLU GLU PHE SEQRES 21 A 322 CYS ARG ARG LEU LYS GLU GLY THR ARG MET ARG ALA PRO SEQRES 22 A 322 ASP TYR THR THR PRO GLU MET TYR GLN THR MET LEU ASP SEQRES 23 A 322 CYS TRP HIS GLY GLU PRO SER GLN ARG PRO THR PHE SER SEQRES 24 A 322 GLU LEU VAL GLU HIS LEU GLY ASN LEU LEU GLN ALA ASN SEQRES 25 A 322 ALA GLN GLN ASP GLU ASN LEU TYR PHE GLN HET F82 A1201 35 HETNAM F82 2-[4-(6,7-DIMETHOXYQUINAZOLIN-4-YL)OXY-2-METHOXY- HETNAM 2 F82 PHENYL]-~{N}-(1-PROPAN-2-YLPYRAZOL-4-YL)ETHANAMIDE FORMUL 2 F82 C25 H27 N5 O5 FORMUL 3 HOH *128(H2 O) HELIX 1 AA1 PRO A 812 LEU A 820 5 9 HELIX 2 AA2 ASP A 823 GLU A 828 1 6 HELIX 3 AA3 PRO A 830 ASP A 832 5 3 HELIX 4 AA4 THR A 875 GLY A 893 1 19 HELIX 5 AA5 ASN A 923 LYS A 931 1 9 HELIX 6 AA6 PRO A 942 LYS A 997 5 6 HELIX 7 AA7 THR A 1001 ARG A 1022 1 22 HELIX 8 AA8 ALA A 1030 ARG A 1032 5 3 HELIX 9 AA9 GLU A 1038 ASN A 1040 5 3 HELIX 10 AB1 PHE A 1047 ARG A 1051 5 5 HELIX 11 AB2 PRO A 1068 MET A 1072 5 5 HELIX 12 AB3 ALA A 1073 ARG A 1080 1 8 HELIX 13 AB4 THR A 1083 SER A 1100 1 18 HELIX 14 AB5 ASP A 1112 GLY A 1122 1 11 HELIX 15 AB6 THR A 1132 TRP A 1143 1 12 HELIX 16 AB7 GLU A 1146 ARG A 1150 5 5 HELIX 17 AB8 THR A 1152 ALA A 1168 1 17 SHEET 1 AA1 5 LEU A 834 PRO A 839 0 SHEET 2 AA1 5 GLY A 846 PHE A 854 -1 O ASP A 852 N LYS A 835 SHEET 3 AA1 5 CYS A 862 LEU A 870 -1 O VAL A 867 N ILE A 849 SHEET 4 AA1 5 MET A 913 GLU A 917 -1 O VAL A 914 N LYS A 868 SHEET 5 AA1 5 LEU A 901 CYS A 905 -1 N LEU A 902 O ILE A 915 SHEET 1 AA2 2 ILE A1034 LEU A1036 0 SHEET 2 AA2 2 VAL A1042 ILE A1044 -1 O LYS A1043 N LEU A1035 SHEET 1 AA3 2 VAL A1060 LYS A1062 0 SHEET 2 AA3 2 ALA A1065 LEU A1067 -1 O LEU A1067 N VAL A1060 CISPEP 1 GLY A 841 ARG A 842 0 1.10 CISPEP 2 ALA A 941 PRO A 942 0 1.66 SITE 1 AC1 20 LEU A 840 VAL A 848 ALA A 866 VAL A 867 SITE 2 AC1 20 LYS A 868 GLU A 885 LEU A 889 VAL A 898 SITE 3 AC1 20 VAL A 899 VAL A 914 VAL A 916 GLU A 917 SITE 4 AC1 20 CYS A 919 LYS A 920 HIS A1026 LEU A1035 SITE 5 AC1 20 CYS A1045 ASP A1046 PHE A1047 HOH A1356 CRYST1 52.104 56.457 60.714 90.00 110.45 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019192 0.000000 0.007157 0.00000 SCALE2 0.000000 0.017713 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017579 0.00000